The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. (19th May 2021)

• Record Type: Journal Article
• Authors: Lee, Yi-Te; Wang, Jasmine J; Luu, Michael; Noureddin, Mazen; Kosari, Kambiz; Agopian, Vatche G; Rich, Nicole E; Lu, Shelly C; Tseng, Hsian-Rong; Nissen, Nicholas N; Singal, Amit G; Yang, Ju Dong
• Is Part Of: Journal of the National Cancer Institute. Volume 113:Number 11(2021)
• Page Start: 1531
• Page End: 1541
• Publication Date: 2021-05-19
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djab079
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: Background: Recent trends of hepatocellular carcinoma (HCC) mortality and outcome remain unknown in the United States. We investigated the recent trends of primary liver cancer (excluding intrahepatic cholangiocarcinoma) mortality and HCC stage, treatment, and overall survival (OS) in the United States. Methods: The National Center for Health Statistics Database was analyzed to investigate the trend of primary liver cancer mortality. We analyzed the Surveillance, Epidemiology, and End Results 18 Database to assess the temporal trend of tumor size, stage, treatment, and OS of HCC. We investigated the association between HCC diagnosis year and OS using Cox regression analysis. All statistical tests were 2-sided. Results: During 2000-2018, liver cancer mortality rates increased until 2013, plateaued during 2013-2016 (annual percent change = 0.1%/y, 95% confidence interval [CI] = −2.1%/y to 2.4%/y, P = .92), and started to decline during 2016-2018 (annual percent change = −1.5%/y, 95% CI = −3.2%/y to 0.2%/y, P = .08). However, mortality continues to increase in American Indian and Alaska Native, individuals aged 65 years or older, and in 33 states. There was a 0.61% (95% CI = 0.53% to 0.69%, P < .001) increase in localized stage HCC and a 0.86-mm (95% CI = −1.10 to −0.62 mm, P < .001) decrease in median tumor size per year. The 1-year OS rate increased from 36.3% (95% CI = 34.3% to 38.3%) to 58.1% (95% CI = 56.9% to 59.4%) during 2000-2015, and the 5-year OS rate almost doubled from 11.7% (95% CI = 10.4% to 13.1%) to 21.3% (95% CI = 20.2% to 22.4%) during 2000-2011. Diagnosis year (per year) (adjusted hazard ratio = 0.96, 95% CI = 0.96 to 0.97) was independently associated with OS in multivariable analysis. Conclusions: Primary liver cancer mortality rates have started to decline in the United States with demographic and state-level variation. With an increasing detection of localized HCC, the OS of HCC has improved over the past decades.